HALO
Halozyme Therapeutics Inc
110.80$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +6.5% | -14.8% | +18.1% | +25.4% | +2.7% | -11.1% | +23.0% | +8.8% | +27.5% | -16.6% | +27.7% | – | |
| – | -4.6% | -11.9% | +24.5% | -13.8% | -14.9% | +57.3% | -3.1% | -13.8% | +42.6% | +0.6% | -0.1% | – | |
| – | +10.3% | -15.7% | +16.2% | +38.3% | +6.4% | -22.4% | +31.7% | +14.3% | +24.7% | -20.2% | +35.1% | – | |
| – | +23.2% | -10.4% | +10.1% | -12.3% | +10.7% | -27.6% | +18.5% | -1.7% | +84.9% | -19.9% | +8.2% | – | |
| – | +6.6% | -6.6% | +1.6% | +15.5% | +2.4% | +0.3% | -1.8% | +10.8% | +67.1% | -24.9% | -1.5% | – | |
| – | +5.2% | -29.3% | +4.6% | +36.5% | +3.9% | -29.0% | +3.5% | +37.1% | +63.1% | -14.6% | +1.1% | – | |
| – | +14.4% | -5.4% | +22.7% | +39.2% | +7.5% | -19.4% | +43.0% | +7.6% | +10.5% | -23.3% | +55.9% | – | |
| – | +15.9% | -13.7% | +0.4% | +0.0% | +0.4% | -0.3% | -2.9% | -2.2% | +14.3% | +12.2% | +1.5% | – | |
| – | -0.6% | -5.1% | +22.6% | +40.3% | +7.9% | -19.3% | +42.5% | +6.8% | -146.1% | – | +58.0% | – | |
| – | -20.8% | +21.7% | +27.6% | +14.9% | +46.4% | -37.5% | +54.6% | +9.9% | -6.8% | -25.7% | +81.6% | – | |
| – | +4.3% | -10.0% | +21.4% | +46.9% | +0.0% | -13.8% | +39.9% | +6.1% | -180.8% | – | +53.2% | – | |
| – | -1.7% | -5.0% | +18.1% | +33.2% | +6.9% | -16.9% | +36.1% | +6.0% | -128.4% | – | +47.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.